• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

子宫内膜癌中细胞内半乳糖凝集素-8 和 -9 的表达。

Expression of Intracellular Galectin-8 and -9 in Endometrial Cancer.

机构信息

Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany.

Institute of Pathology, TUM School of Medicine and Health, Trogerstraße 18, 81675 Munich, Germany.

出版信息

Int J Mol Sci. 2024 Jun 24;25(13):6907. doi: 10.3390/ijms25136907.

DOI:10.3390/ijms25136907
PMID:39000016
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11241125/
Abstract

Endometrial cancer (EC) is a common gynecological cancer worldwide. Treatment has been improved in recent years; however, in advanced stages, therapeutic options are still limited. The expression of galectins is increased in several tumor types and that they are involved in important cell processes. Large studies on endometrial cancer are still pending; Specimens of 225 patients with EC were immunohistochemically stained with antibodies for Gal-8 and Gal-9. Expression was correlated with histopathological variables. The cytosolic expression of both galectins is associated with grading and survival. Cytosolic Galectin-8 expression is a positive prognostic factor for overall survival (OS) and progression-free survival (PFS), while nuclear Gal-8 expression correlates only to OS. The cytosolic presence of Galectin-9 is correlated with a better prognosis regarding OS. Our results suggest that expression of both galectins is associated with OS and PFS in EC. Further studies are needed to understand the underlying molecular mechanisms.

摘要

子宫内膜癌（EC）是一种常见的妇科癌症。近年来治疗有所改善；然而，在晚期，治疗选择仍然有限。几种肿瘤类型中 galectin 的表达增加，它们参与重要的细胞过程。关于子宫内膜癌的大型研究仍在进行中；对 225 例 EC 患者的标本进行了 Gal-8 和 Gal-9 抗体的免疫组织化学染色。表达与组织病理学变量相关。两种半乳糖凝集素的细胞质表达与分级和生存相关。细胞质半乳糖凝集素-8 的表达是总生存（OS）和无进展生存（PFS）的阳性预后因素，而核半乳糖凝集素-8 的表达仅与 OS 相关。Galectin-9 的细胞质存在与 OS 相关的更好的预后。我们的研究结果表明，半乳糖凝集素的表达与 EC 的 OS 和 PFS 相关。需要进一步研究以了解潜在的分子机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24f3/11241125/910a889f0e32/ijms-25-06907-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24f3/11241125/115d33ad72d7/ijms-25-06907-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24f3/11241125/6ea96192a5d1/ijms-25-06907-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24f3/11241125/7a403bfc4d90/ijms-25-06907-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24f3/11241125/2dd51aae7e06/ijms-25-06907-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24f3/11241125/910a889f0e32/ijms-25-06907-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24f3/11241125/115d33ad72d7/ijms-25-06907-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24f3/11241125/6ea96192a5d1/ijms-25-06907-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24f3/11241125/7a403bfc4d90/ijms-25-06907-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24f3/11241125/2dd51aae7e06/ijms-25-06907-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/24f3/11241125/910a889f0e32/ijms-25-06907-g005.jpg

相似文献

1
Expression of Intracellular Galectin-8 and -9 in Endometrial Cancer.子宫内膜癌中细胞内半乳糖凝集素-8 和 -9 的表达。
Int J Mol Sci. 2024 Jun 24;25(13):6907. doi: 10.3390/ijms25136907.
2
Galectins-1, -3, and -7 Are Prognostic Markers for Survival of Ovarian Cancer Patients.半乳糖凝集素-1、-3和-7是卵巢癌患者生存的预后标志物。
Int J Mol Sci. 2017 Jun 8;18(6):1230. doi: 10.3390/ijms18061230.
3
Overall Survival of Ovarian Cancer Patients Is Determined by Expression of Galectins-8 and -9.卵巢癌患者的总生存由半乳糖凝集素-8 和 -9 的表达决定。
Int J Mol Sci. 2018 Jan 22;19(1):323. doi: 10.3390/ijms19010323.
4
Galectin-8 predicts postoperative recurrence of patients with localized T1 clear cell renal cell carcinoma.半乳糖凝集素-8可预测局限性T1期透明细胞肾细胞癌患者的术后复发情况。
Urol Oncol. 2015 Mar;33(3):112.e1-8. doi: 10.1016/j.urolonc.2014.11.001. Epub 2014 Nov 5.
5
Co-expression of galectin-3 and CRIP-1 in endometrial cancer: prognostic value and patient survival.半乳糖凝集素-3和CRIP-1在子宫内膜癌中的共表达：预后价值与患者生存情况
Med Oncol. 2016 Jan;33(1):8. doi: 10.1007/s12032-015-0723-7. Epub 2015 Dec 26.
6
Clinical significance of galectin-7 in epithelial ovarian cancer.Galectin-7 在卵巢上皮性癌中的临床意义。
Anticancer Res. 2013 Apr;33(4):1555-61.
7
Galectin signatures contribute to the heterogeneity of breast cancer and provide new prognostic information and therapeutic targets.半乳糖凝集素特征促成了乳腺癌的异质性，并提供了新的预后信息和治疗靶点。
Oncotarget. 2016 Apr 5;7(14):18183-203. doi: 10.18632/oncotarget.7784.
8
The expression of Galectin-3 in endometrial cancer: a systematic review of the literature.Galectin-3 在子宫内膜癌中的表达：文献系统综述。
Mol Biol Rep. 2021 Jul;48(7):5699-5705. doi: 10.1007/s11033-021-06536-1. Epub 2021 Jul 9.
9
The Significance of Galectin-1 and Galectin-9 Expression in Endometrial Carcinoma.Galectin-1 和 Galectin-9 在子宫内膜癌中的表达意义。
Gynecol Obstet Invest. 2020;85(1):34-40. doi: 10.1159/000502787. Epub 2019 Sep 5.
10
Galectin-8 and -9 as prognostic factors for cervical cancer.半乳糖凝集素-8 和 -9 作为宫颈癌的预后因素。
Arch Gynecol Obstet. 2022 Oct;306(4):1211-1220. doi: 10.1007/s00404-022-06449-9. Epub 2022 Apr 4.

引用本文的文献

1
New insights on Galectin-9 expression in cancer prognosis: An updated systemic review and meta-analysis.半乳糖凝集素-9表达在癌症预后中的新见解：一项更新的系统评价和荟萃分析。
PLoS One. 2025 Mar 26;20(3):e0320441. doi: 10.1371/journal.pone.0320441. eCollection 2025.

本文引用的文献

1
The role of galectins in mediating the adhesion of circulating cells to vascular endothelium.半乳糖凝集素在调节循环细胞黏附血管内皮中的作用。
Front Immunol. 2024 May 22;15:1395714. doi: 10.3389/fimmu.2024.1395714. eCollection 2024.
2
Discovery of galectin-8 as an LILRB4 ligand driving M-MDSCs defines a class of antibodies to fight solid tumors.发现半乳糖凝集素-8 作为 LILRB4 的配体驱动 M-MDSCs，定义了一类用于治疗实体瘤的抗体。
Cell Rep Med. 2024 Jan 16;5(1):101374. doi: 10.1016/j.xcrm.2023.101374.
3
Galectin-8 alters immune microenvironment and promotes tumor progression.
半乳糖凝集素-8改变免疫微环境并促进肿瘤进展。
Am J Cancer Res. 2023 Jun 15;13(6):2517-2529. eCollection 2023.
4
Galectin-8 and -9 as prognostic factors for cervical cancer.半乳糖凝集素-8 和 -9 作为宫颈癌的预后因素。
Arch Gynecol Obstet. 2022 Oct;306(4):1211-1220. doi: 10.1007/s00404-022-06449-9. Epub 2022 Apr 4.
5
The expression of Galectin-3 in endometrial cancer: a systematic review of the literature.Galectin-3 在子宫内膜癌中的表达：文献系统综述。
Mol Biol Rep. 2021 Jul;48(7):5699-5705. doi: 10.1007/s11033-021-06536-1. Epub 2021 Jul 9.
6
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.ESGO/ESTRO/ESP 子宫内膜癌管理指南。
Int J Gynecol Cancer. 2021 Jan;31(1):12-39. doi: 10.1136/ijgc-2020-002230. Epub 2020 Dec 18.
7
Human galectin-16 has a pseudo ligand binding site and plays a role in regulating c-Rel-mediated lymphocyte activity.人类半乳糖凝集素-16具有一个假配体结合位点，并在调节c-Rel介导的淋巴细胞活性中发挥作用。
Biochim Biophys Acta Gen Subj. 2021 Jan;1865(1):129755. doi: 10.1016/j.bbagen.2020.129755. Epub 2020 Oct 2.
8
FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis.美国食品药品监督管理局批准摘要：帕博利珠单抗联合乐伐替尼治疗子宫内膜癌，一项“奥比斯计划”下的国际合作审评。
Clin Cancer Res. 2020 Oct 1;26(19):5062-5067. doi: 10.1158/1078-0432.CCR-19-3979. Epub 2020 Apr 15.
9
Sweetening the hallmarks of cancer: Galectins as multifunctional mediators of tumor progression.甜蜜的癌症特征：半乳糖凝集素作为肿瘤进展的多功能介质。
J Exp Med. 2020 Feb 3;217(2). doi: 10.1084/jem.20182041.
10
Clinical outcome of recurrent endometrial cancer: analysis of post-relapse survival by pattern of recurrence and secondary treatment.复发性子宫内膜癌的临床结局：基于复发模式和二线治疗的复发后生存分析。
Int J Gynecol Cancer. 2020 Feb;30(2):193-200. doi: 10.1136/ijgc-2019-000822. Epub 2019 Dec 1.